Evidence map›Paper›PMID 9109436›Full record

ArticleThe Journal of clinical investigation1997

Markedly reduced activity of mutant calcium-sensing receptor with an inserted Alu element from a kindred with familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism.

M Bai, N Janicic, S Trivedi, S J Quinn, D E Cole, E M Brown, G N Hendy

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 96 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. GPCRs: The most promiscuous druggable receptor of the mankind.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2021
    Review
  5. Treatment of Autosomal Dominant Hypocalcemia Type 1 With the Calcilytic NPSP795 (SHP635).Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2019
    Article
  6. Structural Variation ofGenomics & informatics · 2016
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Intermolecular interactions between dimeric calcium-sensing receptor monomers are important for its normal function.Proceedings of the National Academy of Sciences of the United States of America · 1999
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

M BaiDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
N Janicic
S Trivedi
S J Quinn
D E Cole
E M Brown
G N Hendy
Brigham and Women's Hospital · USMcGill University · CAHarvard University · USUniversity of Toronto · CA

Funding

THE PHARMACOLOGY OF BOVINE PARATHYROID CA++'RECEPTORS'R01DK041415 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BROWN, EDWARD M M · 1989 to 2002
$757k
MUTANT CALCIUM SENSING RECEPTORF32DK009436 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BAI, MEI · 1996 to 1997
–
PHOSPHOLIPASES AND CA++/REGULATED PARATHYROID FUNCTIONR01DK044588 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BROWN, EDWARD M M · 1992 to 1995
–
NIDDK NIH HHS DK09436NIDDK NIH HHS DK41415NIDDK NIH HHS DK44588
6 · The paper itself

Abstract

Missense mutations have been identified in the coding region of the extracellular calcium-sensing receptor (CASR) gene and cause human autosomal dominant hypo- and hypercalcemic disorders. The functional effects of several of these mutations have been characterized in either Xenopus laevis oocytes or in human embryonic kidney (HEK293) cells. All of the mutations that have been examined to date, however, cause single putative amino acid substitutions. In this report, we studied a mutant CASR with an Alu-repetitive element inserted at codon 876, which was identified in affected members of families with the hypercalcemic disorders, familial hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHPT), to understand how this insertion affects CASR function. After cloning of the Alu-repetitive element into the wild-type CASR cDNA, we transiently expressed the mutant receptor in HEK293 cells. Expression of mutant and wild-type receptors was assessed by Western analysis, and the effects of the mutation on extracellular calcium (Ca2+(o)) and gadolinium (Gd3+(o)) elicited increases in the cytosolic calcium concentration (Ca2+(i)) were examined in fura-2-loaded cells using dual wavelength fluorimetry. The insertion resulted in truncated receptor species that had molecular masses some 30 kD less than that of the wild-type CASR and exhibited no Ca2+(i) responses to either Ca2+(o) or Gd3+(o). A similar result was observed with a mutated CASR truncated at residue 876. However, the Alu mutant receptor had no impact on the function of the coexpressed wild-type receptor. Interestingly, the Alu mutant receptor demonstrated decreased cell surface expression relative to the wild-type receptor, whereas the CASR (A877stop) mutant exhibited increased cell surface expression. Thus, like the missense mutations that have been characterized to date in families with FHH, the Alu insertion in this family is a loss-of-function mutation that produces hypercalcemia by reducing the number of normally functional CASRs on the surface of parathyroid and kidney cells. In vitro transcription of exon 7 of the CASR containing the Alu sequence yielded the full-length mutant product and an additional shorter product that was truncated due to stalling of the polymerase at the poly(T) tract. In vitro translation of the mutant transcript yielded three truncated protein products representing termination in all three reading frames at stop codons within the Alu insertion. Thus sequences within the Alu contribute to slippage or frameshift mutagenesis during transcription and/or translation.

Indexed as

AnimalsBase SequenceCalciumCell LineDNA, ComplementaryDNA PrimersGenes, DominantGlycosylationHumansHypercalcemiaHyperparathyroidismImmunohistochemistryInfant, NewbornMutationReceptors, Calcium-SensingReceptors, Cell SurfaceCalciumDNA, ComplementaryDNA PrimersReceptors, Calcium-SensingReceptors, Cell SurfaceTunicamycin

Identifiers

PMID9109436
PMCPMC508016
OpenAlexW2075307506

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.